Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prolonged response to pembrolizumab in BRAFV600E microsatellite stable metastatic colorectal cancer following an increase in tumor mutational burden.

The oncologist - 8 May 2026

Yang Yu-Hsuen, Starling Naureen, Cartwright Elizabeth

Abstract excerpt

BRAFV600E-mutant metastatic colorectal cancer (mCRC) is an aggressive molecular subtype associated with poor prognosis and relative chemoresistance. Outcomes following progression on chemotherapy and MAPK-targeted therapy with encorafenib plus cetuximab remain poor, highlighting an unmet need for effective later-line treatments. Immune checkpoint inhibitors have limited activity in microsatellite-stable (MSS)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 42093086
DOI: 10.1093/oncolo/oyag161
PMCID: PMC13224391

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prolonged response to pembrolizumab in BRAFV600E microsatellite stable metastatic colorectal cancer following an increase in tumor mutational burden.PMID 42093086Read ↗

Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomesSemantic proximity Read ↗

The Evolving Treatment Landscape in BRAF-V600E-Mutated Metastatic Colorectal Cancer.Semantic proximity Read ↗

High tumor mutational burden assessed through next-generation sequencing predicts favorable survival in microsatellite stable metastatic colon cancer patients.Semantic proximity Read ↗

Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer.Semantic proximity Read ↗

Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibitionSemantic proximity Read ↗

High tumor mutation burden (TMB) in microsatellite stable (MSS) colorectal cancers: Diverse molecular associations point to variable pathophysiology.Semantic proximity Read ↗

Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers.Semantic proximity Read ↗

The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?Semantic proximity Read ↗

Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: A case report.Semantic proximity Read ↗

Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR statusSemantic proximity Read ↗

Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal CancerSemantic proximity Read ↗

Colorectal cancer with BRAF V600E mutation: Trends in immune checkpoint inhibitor treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.